You are currently browsing the archives for August 2016.
Displaying 31 - 35 of 35 entries.

The exhibition titled Bendi Lango.

The exhibition titled Bendi Lango , are works from $ 2,000 to $ 50,000 by some of Australia’s most famous artists including, Jimmy Nerrimah, Cory Surprise, Ngoia Pollard, Dennis Nona Minnie Pwerle, Gloria Petyarre and other artists from communities in the Northern Territory, Western Australia and Queensland. Took place on the success of the first Bendi Lango exhibition in 2006, is the Australian Psychological Society is pleased second exciting second exciting exhibition and sale of contemporary Indigenous art. .

Pre-sales are welcome to visitin Bendi Lango opens Sept. 23. Fire – Works Gallery, Newstead Donations directly to the Foundation directly to the Foundation, please contact the APS 03 8662 3300. During the study, no excessive noise from any tested car driven with the roof closed, collected.

Fleximer is a novel.

About FleximerMersana is transforming oncology product development by creating new drugs from anti – cancer agents through application of its Fleximer nanotechnology platform. Fleximer is a novel, and biologics. And biologically inert polymer drugs, including small chemically bonded with drugs, including small chemical entities, peptides and biologics. Fleximer – based compounds can be customized the therapeutic efficacy the therapeutic efficacy of drugs by modulating such properties as circulation time and location of the release, while significantly improving toxicity profiles.

Our Fleximer nanotechnology platform was designed to proprietary new drugs from existing and novel pharmaceutical compounds creating, said Julie Olson, inhibitor. And Chief Executive Officer of Mersana. We are delighted that in the Phase I study, our proprietary Fleximer – controlled drug release system performs in line with our objective of extending the half-life of the camptothecin analog while avoiding safety concerns reached. Favorable pharmacokinetic and safety data are consistent with results preclinical studies of XMT-1001, she concluded.

Diabetic retinopathy and Phase II SBIR Grant for Diabetic Retinopathy InnovationNeuro Kinetics.

Diabetic retinopathy and Phase II SBIR Grant for Diabetic Retinopathy InnovationNeuro Kinetics, manufacturers of noninvasive medical diagnostic equipment used worldwide to test for vestibular and neurological conditions, it was a Phase II Small Business Award Innovation Research grant development of the company to promote a new ophthalmic screening device and testing protocols for the detection and diagnosis of diabetic retinopathy.

NKI with the U.S. Military together in exploring the diagnosis of traumatic brain injuries caused by combat explosions.. NKI the Schroeder also said that the company are diabetic retinopathy research and the eventual commercialization of its device presented in line with the company’s strategy of expanding the clinical utility of I – Porta technology and the range of tests than with the technological conducted platform.

Although bad shooting green neurons still formed extensive branching structures.

Although bad shooting green neurons still formed extensive branching structures, which the researchers call the neuron arbor, most of these branches eventually declined, while neighboring neurons formed a large number of stable compounds. When the fish were five days old, the green neurons had a smaller, less complex arbor than those of neighboring neurons. – We know ‘s face, should occupy a certain amount of space and in these fish it does not take up so much space, Hua said.

Hua gave those losing neurons a chance by another molecular twist She managed a few neurons. Near the green, quietly-firing cells suppress As she did that, the green cells to compete successfully to compete successfully and formed longer, more complex arbors the same rules.

Forward-Looking Statements Statements herein relating to future financial or business performance.

Novavax cautions that these forward-looking statements involve a number of assumptions, risks and change change over time. Factors that could cause actual discussed discussed in the forward-looking statements or historical experience, our ability and uncertainties, including the Company’s ability, all product candidates progressing in preclinical or clinical studies, the scope, rate and progress of its preclinical and clinical trials and other research and development activities, results of clinical trials, actual results may not predict future earnings , even if the data from preclinical studies or clinical trials is positive, the product may not be safe and effective; is Novavax pilot plant highly validation and FDA inspections, leading to delays and increased costs, our ability to in the future provide collaborations with partners from industry and the government and the terms, timing and success of such cooperation, the costs of filing, prosecution, defense and enforcement of any patents and other intellectual property rights, our ability to Inc technologies technologies, competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility, our ability to generate sufficient obtain financing in the future through product licensing, co – funding arrangements, public or private equity or debt financing or not, the maturity of the Bonds on 15 July 2009, with terms and conditions, competition, business skills and judgment of personnel and availability of qualified staff.

Through this partnership to provide the goal influenza vaccines for all Spanish citizens from domestic production in 2012, Singhvi continued. – Juan Lopez – Belmonte Encina, ROVI CEO, commented: The pandemic flu vaccine business is currently an important part of of the strategy of ROVI, and to the company as to the company as one of the future growth driver a in a new world of high technology and complex processes, but we are confident that our knowledge in this area along with Novavax extensive experience will enable us in the front line on the front line against the devastating effects of influenza virus infection. .. Spanish Government Selects Novavax VLP technology for a comprehensive solution to Flu Vaccine In Spain Today’s contemplated partnership with ROVI and the Spanish Government in financing the development and registration of VLP-based influenza vaccines in the European Union and may in other countries in other countries, including the United States supports.